Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 12/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 5/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748739 | 0.74 | CCR2 (0.50) | CCR2HTTRAB9AMMP1 | |
| SCHEMBL3742893 | 0.73 | CCR2 (0.34) | CCR2 | |
| SCHEMBL13483780 | 0.73 | CCR2 (0.55) | CCR2HTTRAB9ANPC1 | |
| SCHEMBL12799205 | 0.73 | CCR2 (0.55) | CCR2HTTRAB9ANPC1 | |
| SCHEMBL13006180 | 0.71 | CCR2 (1.00) | CCR2RAB9ANPC1 | |
| SCHEMBL242474 | 0.71 | CCR2 (1.00) | CCR2RAB9ANPC1 | |
| SCHEMBL12061277 | 0.71 | CCR2 (1.00) | CCR2RAB9ANPC1 | |
| SCHEMBL13761535 | 0.70 | CCR2 (0.63) | CCR2HTTRAB9A | |
| SCHEMBL7751169 | 0.70 | CCR2 (0.63) | CCR2HTTRAB9A | |
| SCHEMBL12061252 | 0.70 | CCR2 (0.97) | CCR2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497261-B2 | 3-aminocaprolactam compounds for treating inflammatory disorders | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-30 | — | — | US | claimed |
| US-20100292213-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-11-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292213-A1 | Anti-Inflammatory Agents | TNF, IL1RN, IL1R1 | CCR2 121/4885HTT 3616/4885RAB9A 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.